
Alcohol Addiction Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Description
Alcohol Addiction Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Alcohol Addiction - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Alcohol Addiction (Central Nervous System) pipeline landscape.
Alcohol addiction refers to a psychological and physical dependency on alcohol. Symptoms include decreased involvement in extracurricular activities, depression, restlessness, inability to control drinking and violent behavior. Risk factors include age, family history and depression and other mental health problems.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Alcohol Addiction - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Alcohol Addiction (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Alcohol Addiction (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Alcohol Addiction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 11, 6, 2, 29, 3 and 2 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 4 and 1 molecules, respectively.
Alcohol Addiction (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Alcohol Addiction - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Alcohol Addiction (Central Nervous System) pipeline landscape.
Alcohol addiction refers to a psychological and physical dependency on alcohol. Symptoms include decreased involvement in extracurricular activities, depression, restlessness, inability to control drinking and violent behavior. Risk factors include age, family history and depression and other mental health problems.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Alcohol Addiction - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Alcohol Addiction (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Alcohol Addiction (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Alcohol Addiction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 11, 6, 2, 29, 3 and 2 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 4 and 1 molecules, respectively.
Alcohol Addiction (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Alcohol Addiction (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Alcohol Addiction (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Alcohol Addiction (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Alcohol Addiction (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Alcohol Addiction (Central Nervous System)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Alcohol Addiction (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Alcohol Addiction (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
Companies Mentioned
Addex Therapeutics Ltd
Adial Pharmaceuticals Inc
Alar Pharmaceuticals Inc
Aptinyx Inc
Astellas Pharma Inc
Astraea Therapeutics LLC
Avicanna Inc
AWAKN Life Sciences Corp
BioCorRx Inc
Bioprojet SCR
Ceruvia Lifesciences LLC
Chronos Therapeutics Ltd
Clairvoyant Therapeutics Inc
Clearmind Medicine Inc
Colorado Research Partners LLC
Confluence Pharmaceuticals LLC
Corcept Therapeutics Inc
Curemark LLC
Cybin Inc
Eli Lilly and Co
Journey Colab Corp
Kinnov Therapeutics
Kinoxis Therapeutics Pty Ltd
Kyorin Pharmaceutical Co Ltd
Laboratorio Farmaceutico CT Srl
Lohocla Research Corp
Mapreg SAS
Mind Medicine MindMed Inc
Montisera Ltd
Naprogenix Inc
Neuroepigenix LLC
Novo Nordisk AS
Omeros Corp
Opiant Pharmaceuticals Inc
Orphomed Inc
Osmotica Pharmaceutical Corp
Palisades Therapeutics
Pfizer Inc
Protagenic Therapeutics Inc
Psilera Inc
Sage Therapeutics Inc
SK Biopharmaceuticals Co Ltd
Sobrera Pharma AB
South Plains Biotechnology Inc
Syntropharma Ltd
Tonix Pharmaceuticals Holding Corp
VM Discovery Inc
Whan In Pharm Co Ltd
Zynerba Pharmaceuticals Inc
Companies Mentioned
Addex Therapeutics Ltd
Adial Pharmaceuticals Inc
Alar Pharmaceuticals Inc
Aptinyx Inc
Astellas Pharma Inc
Astraea Therapeutics LLC
Avicanna Inc
AWAKN Life Sciences Corp
BioCorRx Inc
Bioprojet SCR
Ceruvia Lifesciences LLC
Chronos Therapeutics Ltd
Clairvoyant Therapeutics Inc
Clearmind Medicine Inc
Colorado Research Partners LLC
Confluence Pharmaceuticals LLC
Corcept Therapeutics Inc
Curemark LLC
Cybin Inc
Eli Lilly and Co
Journey Colab Corp
Kinnov Therapeutics
Kinoxis Therapeutics Pty Ltd
Kyorin Pharmaceutical Co Ltd
Laboratorio Farmaceutico CT Srl
Lohocla Research Corp
Mapreg SAS
Mind Medicine MindMed Inc
Montisera Ltd
Naprogenix Inc
Neuroepigenix LLC
Novo Nordisk AS
Omeros Corp
Opiant Pharmaceuticals Inc
Orphomed Inc
Osmotica Pharmaceutical Corp
Palisades Therapeutics
Pfizer Inc
Protagenic Therapeutics Inc
Psilera Inc
Sage Therapeutics Inc
SK Biopharmaceuticals Co Ltd
Sobrera Pharma AB
South Plains Biotechnology Inc
Syntropharma Ltd
Tonix Pharmaceuticals Holding Corp
VM Discovery Inc
Whan In Pharm Co Ltd
Zynerba Pharmaceuticals Inc
Table of Contents
130 Pages
- Introduction
- Global Markets Direct Report Coverage
- Alcohol Addiction - Overview
- Alcohol Addiction - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Alcohol Addiction - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Alcohol Addiction - Companies Involved in Therapeutics Development
- Addex Therapeutics Ltd
- Adial Pharmaceuticals Inc
- Alar Pharmaceuticals Inc
- Aptinyx Inc
- Astellas Pharma Inc
- Astraea Therapeutics LLC
- Avicanna Inc
- AWAKN Life Sciences Corp
- BioCorRx Inc
- Bioprojet SCR
- Ceruvia Lifesciences LLC
- Chronos Therapeutics Ltd
- Clairvoyant Therapeutics Inc
- Clearmind Medicine Inc
- Colorado Research Partners LLC
- Confluence Pharmaceuticals LLC
- Corcept Therapeutics Inc
- Curemark LLC
- Cybin Inc
- Eli Lilly and Co
- Journey Colab Corp
- Kinnov Therapeutics
- Kinoxis Therapeutics Pty Ltd
- Kyorin Pharmaceutical Co Ltd
- Laboratorio Farmaceutico CT Srl
- Lohocla Research Corp
- Mapreg SAS
- Mind Medicine MindMed Inc
- Montisera Ltd
- Naprogenix Inc
- Neuroepigenix LLC
- Novo Nordisk AS
- Omeros Corp
- Opiant Pharmaceuticals Inc
- Orphomed Inc
- Osmotica Pharmaceutical Corp
- Palisades Therapeutics
- Pfizer Inc
- Protagenic Therapeutics Inc
- Psilera Inc
- Sage Therapeutics Inc
- SK Biopharmaceuticals Co Ltd
- Sobrera Pharma AB
- South Plains Biotechnology Inc
- Syntropharma Ltd
- Tonix Pharmaceuticals Holding Corp
- VM Discovery Inc
- Whan In Pharm Co Ltd
- Zynerba Pharmaceuticals Inc
- Alcohol Addiction - Drug Profiles
- (cyproheptadine hydrochloride + prazosin hydrochloride) - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- (varenicline tartrate + bupropion hydrochloride) SR - Drug Profile
- Product Description
- Mechanism Of Action
- acamprosate calcium SR - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- ADX-71441 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- ALA-2000 - Drug Profile
- Product Description
- Mechanism Of Action
- arbaclofen ER - Drug Profile
- Product Description
- Mechanism Of Action
- ASP-8062 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- AT-1001 - Drug Profile
- Product Description
- Mechanism Of Action
- BICX-101 SR - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- BICX-102 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- BP-1.3656B - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- brexanolone - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- CM-1212 - Drug Profile
- Product Description
- Mechanism Of Action
- CMND-100 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- CTDP-002 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- CYB-003 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- D-15 - Drug Profile
- Product Description
- Mechanism Of Action
- DCRALDH-2 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Drugs to Inhibit Fructokinase for Alcohol Addiction - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- GET-73 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- ibudilast - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- JOUR-001 - Drug Profile
- Product Description
- Mechanism Of Action
- JR-220 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- ketamine - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- KNX-100 - Drug Profile
- Product Description
- Mechanism Of Action
- MAP-4343 - Drug Profile
- Product Description
- Mechanism Of Action
- midomafetamine - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- mifepristone - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- MQ-221 - Drug Profile
- Product Description
- Mechanism Of Action
- naltrexone - Drug Profile
- Product Description
- Mechanism Of Action
- naltrexone hydrochloride - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- naltrexone hydrochloride - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- naltrexone LA - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Nezavist - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- NYPRG-101 - Drug Profile
- Product Description
- Mechanism Of Action
- NYX-783 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- odelepran - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- OMS-527 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- ondansetron hydrochloride - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- ORP-106 - Drug Profile
- Product Description
- Mechanism Of Action
- PF-05190457 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Pharmacotherapy for Alcohol Use Disorder - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- PSIL-002 - Drug Profile
- Product Description
- Mechanism Of Action
- psilocybin - Drug Profile
- Product Description
- Mechanism Of Action
- psilocybin - Drug Profile
- Product Description
- Mechanism Of Action
- PT-00114 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- PT-150 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- RC-132 - Drug Profile
- Product Description
- Mechanism Of Action
- RTI-1395133 - Drug Profile
- Product Description
- Mechanism Of Action
- SKL-10406 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Small Molecule to Antagonize Mu Opioid Receptor for Drug Abuse, Alcohol Addiction and OIC - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecule to Antagonize NMDA Receptor and Block Sodium Channels for CNS disorders - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Small Molecules for Alcohol Use Disorder - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Small Molecules for Psychiatric Disorders - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecules To Agonize Nociceptin Receptors For Alcohol Addiction - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecules to Antagonize GABAA1 for Alcohol Addiction and Anxiety - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecules to Antagonize Glucocorticoid Receptor II for Alcohol Dependance - Drug Profile
- Product Description
- Mechanism Of Action
- TNX-102 - Drug Profile
- Product Description
- Mechanism Of Action
- VMD-2202 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- WIL-1903 - Drug Profile
- Product Description
- Mechanism Of Action
- zolunicant hydrochloride - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Alcohol Addiction - Dormant Projects
- Alcohol Addiction - Discontinued Products
- Alcohol Addiction - Product Development Milestones
- Featured News & Press Releases
- Mar 17, 2022: Clearmind Medicine announces positive results on CMND-100 trials
- Feb 28, 2022: MediciNova announces MN-166 (ibudilast) identified as potential beneficial pharmacotherapy for treatment of degenerative cervical myelopathy in Global Spine Journal
- Feb 24, 2022: Adial Pharmaceuticals announces completion of last patient, last visit in its ONWARD phase 3 trial of AD04 for the treatment of patients with alcohol use disorder
- Feb 22, 2022: MediciNova announces MN-166 (ibudilast) identified as promising pharmacotherapy for alcohol use disorder in drugs
- Jan 28, 2022: Clearmind Medicine partners with Dr. Gabor Mate to discuss alcohol use disorder and trauma in a special virtual Event on February 3
- Jan 27, 2022: MediciNova receives a notice of intention to grant for a new patent covering MN-166 (ibudilast) for the treatment of alcohol use disorder in Europe
- Jan 20, 2022: Opiant Pharmaceuticals announces first patient dosed in phase 2 trial of OPNT002, nasal Naltrexone, for alcohol use disorder
- Jan 20, 2022: Clairvoyant Therapeutics receives approval in Canada to initiate a world-leading psilocybin trial for treatment of alcohol use disorder
- Jan 19, 2022: Awakn Life Sciences signs MOU With MAPS
- Jan 11, 2022: Awakn announces positive results from phase II A/B clinical trial
- Dec 08, 2021: Cybin confirms scientific advice meeting with UK Medical and Healthcare Products Regulatory Agency for lead candidate CYB003 for the treatment of major depressive disorder and alcohol use disorder
- Nov 16, 2021: Awakn Life Sciences signs MOU with NHS (Devon Partnership NHS Trust) and University of Exeter with a view of increasing access to psychedelic-assisted psychotherapy in the UK
- Nov 08, 2021: Cybin announces positive CYB003 data demonstrating significant advantages over oral psilocybin for treatment of mental health
- Nov 04, 2021: Awakn Life Sciences announces the findings from phase II A/B study are to be published In American Journal Of Psychiatry
- Oct 26, 2021: Clearmind signs development and supply agreement to produce its drug candidate MEAI psychedelic molecule with Aragen Life Sciences
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Number of Products under Development for Alcohol Addiction, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Companies, 2022 (Contd..1)
- Number of Products under Development by Companies, 2022 (Contd..2)
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Companies, 2022 (Contd..1)
- Products under Development by Companies, 2022 (Contd..2)
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Target, 2022 (Contd..1)
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Alcohol Addiction - Pipeline by Addex Therapeutics Ltd, 2022
- Alcohol Addiction - Pipeline by Adial Pharmaceuticals Inc, 2022
- Alcohol Addiction - Pipeline by Alar Pharmaceuticals Inc, 2022
- Alcohol Addiction - Pipeline by Aptinyx Inc, 2022
- Alcohol Addiction - Pipeline by Astellas Pharma Inc, 2022
- Alcohol Addiction - Pipeline by Astraea Therapeutics LLC, 2022
- Alcohol Addiction - Pipeline by Avicanna Inc, 2022
- Alcohol Addiction - Pipeline by AWAKN Life Sciences Corp, 2022
- Alcohol Addiction - Pipeline by BioCorRx Inc, 2022
- Alcohol Addiction - Pipeline by Bioprojet SCR, 2022
- Alcohol Addiction - Pipeline by Ceruvia Lifesciences LLC, 2022
- Alcohol Addiction - Pipeline by Chronos Therapeutics Ltd, 2022
- Alcohol Addiction - Pipeline by Clairvoyant Therapeutics Inc, 2022
- Alcohol Addiction - Pipeline by Clearmind Medicine Inc, 2022
- Alcohol Addiction - Pipeline by Colorado Research Partners LLC, 2022
- Alcohol Addiction - Pipeline by Confluence Pharmaceuticals LLC, 2022
- Alcohol Addiction - Pipeline by Corcept Therapeutics Inc, 2022
- Alcohol Addiction - Pipeline by Curemark LLC, 2022
- Alcohol Addiction - Pipeline by Cybin Inc, 2022
- Alcohol Addiction - Pipeline by Eli Lilly and Co, 2022
- Alcohol Addiction - Pipeline by Journey Colab Corp, 2022
- Alcohol Addiction - Pipeline by Kinnov Therapeutics, 2022
- Alcohol Addiction - Pipeline by Kinoxis Therapeutics Pty Ltd, 2022
- Alcohol Addiction - Pipeline by Kyorin Pharmaceutical Co Ltd, 2022
- Alcohol Addiction - Pipeline by Laboratorio Farmaceutico CT Srl, 2022
- Alcohol Addiction - Pipeline by Lohocla Research Corp, 2022
- Alcohol Addiction - Pipeline by Mapreg SAS, 2022
- Alcohol Addiction - Pipeline by Mind Medicine MindMed Inc, 2022
- Alcohol Addiction - Pipeline by Montisera Ltd, 2022
- Alcohol Addiction - Pipeline by Naprogenix Inc, 2022
- Alcohol Addiction - Pipeline by Neuroepigenix LLC, 2022
- Alcohol Addiction - Pipeline by Novo Nordisk AS, 2022
- Alcohol Addiction - Pipeline by Omeros Corp, 2022
- Alcohol Addiction - Pipeline by Opiant Pharmaceuticals Inc, 2022
- Alcohol Addiction - Pipeline by Orphomed Inc, 2022
- Alcohol Addiction - Pipeline by Osmotica Pharmaceutical Corp, 2022
- Alcohol Addiction - Pipeline by Palisades Therapeutics, 2022
- Alcohol Addiction - Pipeline by Pfizer Inc, 2022
- Alcohol Addiction - Pipeline by Protagenic Therapeutics Inc, 2022
- Alcohol Addiction - Pipeline by Psilera Inc, 2022
- Alcohol Addiction - Pipeline by Sage Therapeutics Inc, 2022
- Alcohol Addiction - Pipeline by SK Biopharmaceuticals Co Ltd, 2022
- Alcohol Addiction - Pipeline by Sobrera Pharma AB, 2022
- Alcohol Addiction - Pipeline by South Plains Biotechnology Inc, 2022
- Alcohol Addiction - Pipeline by Syntropharma Ltd, 2022
- Alcohol Addiction - Pipeline by Tonix Pharmaceuticals Holding Corp, 2022
- Alcohol Addiction - Pipeline by VM Discovery Inc, 2022
- Alcohol Addiction - Pipeline by Whan In Pharm Co Ltd, 2022
- Alcohol Addiction - Pipeline by Zynerba Pharmaceuticals Inc, 2022
- Alcohol Addiction - Dormant Projects, 2022
- Alcohol Addiction - Dormant Projects, 2022 (Contd..1)
- Alcohol Addiction - Dormant Projects, 2022 (Contd..2)
- Alcohol Addiction - Discontinued Products, 2022
- List of Figures
- Number of Products under Development for Alcohol Addiction, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Molecule Types, 2022
- Number of Products by Stage and Molecule Types, 2022
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.